Please use this identifier to cite or link to this item: https://doi.org/10.1093/nar/gky202
DC FieldValue
dc.titleZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia
dc.contributor.authorTong, Q.
dc.contributor.authorYou, H.
dc.contributor.authorChen, X.
dc.contributor.authorWang, K.
dc.contributor.authorSun, W.
dc.contributor.authorPei, Y.
dc.contributor.authorZhao, X.
dc.contributor.authorYuan, M.
dc.contributor.authorZhu, H.
dc.contributor.authorLuo, Z.
dc.contributor.authorZhang, Y.
dc.date.accessioned2021-12-29T04:42:14Z
dc.date.available2021-12-29T04:42:14Z
dc.date.issued2018
dc.identifier.citationTong, Q., You, H., Chen, X., Wang, K., Sun, W., Pei, Y., Zhao, X., Yuan, M., Zhu, H., Luo, Z., Zhang, Y. (2018). ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia. Nucleic Acids Research 46 (7) : 3284-3297. ScholarBank@NUS Repository. https://doi.org/10.1093/nar/gky202
dc.identifier.issn0305-1048
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/212398
dc.description.abstractDespite All-trans retinoic acid (ATRA) has transformed acute promyelocytic leukemia (APL) from the most fatal to the most curable hematological cancer, there remains a clinical challenge that many high-risk APL patients who fail to achieve a complete molecular remission or relapse and become resistant to ATRA. Herein, we report that 5-(4-methoxyphenethyl)-[1, 3] dioxolo [4, 5-j] phenanthridin-6(5H)-one (ZYH005) exhibits specific anticancer effects on APL and ATRA-resistant APL in vitro and vivo, while shows negligible cytotoxic effect on non-cancerous cell lines and peripheral blood mononuclear cells from healthy donors. Using single-molecule magnetic tweezers and molecule docking, we demonstrate that ZYH005 is a DNA intercalator. Further mechanistic studies show that ZYH005 triggers DNA damage, and caspase-dependent degradation of the PML-RARa fusion protein. As a result, APL and ATRA-resistant APL cells underwent apoptosis upon ZYH005 treatment and this apoptosis-inducing effect is even stronger than that of arsenic trioxide and anticancer agents including 5-fluorouracil, cisplatin and doxorubicin. Moreover, ZYH005 represses leukemia development in vivo and prolongs the survival of both APL and ATRA-resistant APL mice. To our knowledge, ZYH005 is the first synthetic phenanthridinone derivative, which functions as a DNA intercalator and can serve as a potential candidate drug for APL, particularly for ATRA-resistant APL. © The Author(s) 2018.
dc.publisherOxford University Press
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScopus OA2018
dc.typeArticle
dc.contributor.departmentMECHANOBIOLOGY INSTITUTE
dc.description.doi10.1093/nar/gky202
dc.description.sourcetitleNucleic Acids Research
dc.description.volume46
dc.description.issue7
dc.description.page3284-3297
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1093_nar_gky202.pdf5.6 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

6
checked on Sep 23, 2022

Page view(s)

62
checked on Sep 22, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons